Update On Application For Manufacturing And Marketing Approval Of Jr-141 For Treatment Of Mps Ii (Hunter Syndrome) In Brazil
03/08/2022 05:03
Aug 3 (Reuters) - JCR Pharmaceuticals Co Ltd 4552.T :
* UPDATE ON APPLICATION FOR MANUFACTURING AND MARKETING
APPROVAL
OF JR-141 FOR TREATMENT OF MPS II (HUNTER SYNDROME) IN BRAZIL
Source text for Eikon: ID:nTStc7cbf9
Further company coverage: 4552.T
Recent news on JCR Pharmaceuticals
See all newsBrief: JCR Pharmaceuticals Receives Marketing Authorization In Kuwait For Izcargo
Italfarmaco And Jcr Pharmaceuticals Enter Into Exclusive License Agreement For Jr-141 In United States, Europe, And Latin America
Brief: Jcr Pharmaceuticals Receives Orphan Drug Designation For Givinostat In Japan
Brief: Medipal & JCR Dose First Patient In Global Phase I/II Trial OF JR-446 For Mucopolysaccharidosis Type IIIB
Table: Jcr Pharmaceuticals -Q1 group results